Aprogen Medicines Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 37,377.61 million compared to KRW 3,036.15 million a year ago. Net loss was KRW 14,228 million compared to KRW 27,365.97 million a year ago. Basic loss per share from continuing operations was KRW 61 compared to KRW 158 a year ago. Diluted loss per share from continuing operations was KRW 61 compared to KRW 158 a year ago. Basic loss per share was KRW 61 compared to KRW 158 a year ago.
For the six months, sales was KRW 1,034.33 million compared to KRW 562.3 million a year ago. Net loss was KRW 39,554.99 million compared to KRW 52,540.71 million a year ago. Basic loss per share from continuing operations was KRW 170 compared to KRW 303 a year ago. Diluted loss per share from continuing operations was KRW 170 compared to KRW 303 a year ago. Basic loss per share was KRW 170 compared to KRW 303 a year ago.